Literature DB >> 12661179

Analysis of adverse events after anthrax immunization in US Army medical personnel.

Glenn M Wasserman1, John D Grabenstein, Phillip R Pittman, Mark V Rubertone, Paul P Gibbs, Linda Z Wang, Lance G Golder.   

Abstract

A broad range of health effects in a cohort of 601 health care personnel, immunized with anthrax vaccine adsorbed (AVA) as a military occupational health requirement, were assessed to evaluate adverse events both qualitatively and quantitatively. Active surveillance showed that localized reactions were common and occurred more often in women than men. Five patients were reported to the Vaccine Adverse Event Reporting System, but only one event could be definitively attributed to immunization, a large localized reaction. Two separate cohort studies, one using nested data from a standardized health risk appraisal instrument and the other comparing rates of outpatient visits and hospitalizations, did not reveal significant differences between AVA-immunized and unimmunized individuals. Our findings suggest that AVA is relatively reactogenic but do not indicate serious adverse health effects due to immunization.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12661179     DOI: 10.1097/01.jom.0000058345.05741.6b

Source DB:  PubMed          Journal:  J Occup Environ Med        ISSN: 1076-2752            Impact factor:   2.162


  13 in total

1.  Towards a human oral vaccine for anthrax: the utility of a Salmonella Typhi Ty21a-based prime-boost immunization strategy.

Authors:  Leslie W J Baillie; Ana L Rodriguez; Stephen Moore; Helen S Atkins; Chiguang Feng; James P Nataro; Marcela F Pasetti
Journal:  Vaccine       Date:  2008-09-19       Impact factor: 3.641

2.  Surface plasmon resonance measurements of plasma antibody avidity during primary and secondary responses to anthrax protective antigen.

Authors:  Heather E Lynch; Shelley M Stewart; Thomas B Kepler; Gregory D Sempowski; S Munir Alam
Journal:  J Immunol Methods       Date:  2013-12-04       Impact factor: 2.303

3.  Characterization of a multi-component anthrax vaccine designed to target the initial stages of infection as well as toxaemia.

Authors:  C K Cote; L Kaatz; J Reinhardt; J Bozue; S A Tobery; A D Bassett; P Sanz; S C Darnell; F Alem; A D O'Brien; S L Welkos
Journal:  J Med Microbiol       Date:  2012-07-05       Impact factor: 2.472

4.  An anthrax subunit vaccine candidate based on protective regions of Bacillus anthracis protective antigen and lethal factor.

Authors:  Les W Baillie; Theresa B Huwar; Stephen Moore; Gabriela Mellado-Sanchez; Liliana Rodriguez; Brendan N Neeson; Helen C Flick-Smith; Dominic C Jenner; Helen S Atkins; Rebecca J Ingram; Danny M Altmann; James P Nataro; Marcela F Pasetti
Journal:  Vaccine       Date:  2010-08-04       Impact factor: 3.641

5.  Anthrax protective antigen delivered by Salmonella enterica serovar Typhi Ty21a protects mice from a lethal anthrax spore challenge.

Authors:  Manuel Osorio; Yanping Wu; Sunil Singh; Tod J Merkel; Siba Bhattacharyya; Milan S Blake; Dennis J Kopecko
Journal:  Infect Immun       Date:  2009-01-29       Impact factor: 3.441

6.  Comparison of a multiplexed fluorescent covalent microsphere immunoassay and an enzyme-linked immunosorbent assay for measurement of human immunoglobulin G antibodies to anthrax toxins.

Authors:  Raymond E Biagini; Deborah L Sammons; Jerome P Smith; Barbara A MacKenzie; Cynthia A F Striley; Vera Semenova; Evelen Steward-Clark; Karen Stamey; Alison E Freeman; Conrad P Quinn; John E Snawder
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

7.  Unique Inflammatory Mediators and Specific IgE Levels Distinguish Local from Systemic Reactions after Anthrax Vaccine Adsorbed Vaccination.

Authors:  Lori Garman; Kenneth Smith; Emily E Muns; Cathy A Velte; Christina E Spooner; Melissa E Munroe; A Darise Farris; Michael R Nelson; Renata J M Engler; Judith A James
Journal:  Clin Vaccine Immunol       Date:  2016-08-05

Review 8.  Anthrax vaccination strategies.

Authors:  Robert J Cybulski; Patrick Sanz; Alison D O'Brien
Journal:  Mol Aspects Med       Date:  2009-09-01

9.  Evaluation of anthrax vaccine safety in 18 to 20 year olds: A first step towards age de-escalation studies in adolescents.

Authors:  James C King; Yonghong Gao; Conrad P Quinn; Thomas M Dreier; Cabrini Vianney; Eric M Espeland
Journal:  Vaccine       Date:  2015-04-05       Impact factor: 4.169

Review 10.  Alternative pre-approved and novel therapies for the treatment of anthrax.

Authors:  Breanne M Head; Ethan Rubinstein; Adrienne F A Meyers
Journal:  BMC Infect Dis       Date:  2016-11-03       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.